Structural modelling predicts that fibrocystin destabilisation is a pathogenic cause of ARPKD
Destabilisation of fibrocystin may be the predominant pathogenic mechanism in ARPKD survivors, and highlight fibrocystin stabilisation as a therapeutic strategy.